Beyond Air, Inc. (XAIR): Results of Operations and Financial Condition
Beyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Beyond Air ® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million
How this was made
The 30-second read
Why it matters
The 8-K provides fresh quarterly financials, reaffirms revenue guidance, and discloses a new financing package up to $30.1M, including proceeds tied to FDA approval, which can change the probability-weighted outlook for the 2H 2026 launch.
Market read
Traders get a new capital and guidance update tied to an FDA milestone, which can reprice launch timing and dilution expectations.
What to watch
Gross margin remains low (13% vs 9% prior year) and operating losses persist, so the market may focus on burn rate and commercialization traction rather than guidance alone.
Background
Beyond Air is commercial-stage in LungFit PH and is awaiting FDA review of a PMA supplement for its second-generation system submitted in June 2025.
Ticker impact
Beyond Air reports Q2 results, reaffirms 2026 revenue guidance, and discloses up to $30.1M financing tied to FDA approval for its second-generation LungFit PH system.
Likely near-term volatility with a bias to the upside if investors view the financing as de-risking the FDA launch; downside risk if FDA timing slips or warrant-linked dilution concerns dominate.
New primary disclosures include Q2 financials, reaffirmed guidance, and a specific financing structure with $10.0M tied to FDA approval, which can reprice probability-weighted outcomes for the LungFit PH launch.
Market effects
Highlights how FDA review timelines and device PMA supplements can drive capital-market financing structures for commercial-stage medtech.
Limited direct regional impact; primarily affects US-listed small-cap biotech/medtech sentiment.
Mentions distribution coverage across 45+ countries, but near-term catalyst remains FDA approval for the US launch.
Counterpoint
The financing includes warrant exercise optionality and may still imply dilution; investors may discount the $10.0M FDA-linked tranche if approval probability is already priced.
Key entities
- companyBeyond Air, Inc.
NASDAQ-listed medical device and biopharmaceutical company focused on nitric oxide delivery via LungFit PH.
- productLungFit PH second-generation system
FDA-reviewed PMA supplement; approval expected in 2H 2026 and included in 2027 revenue guidance.
- regulatorFDA
Reviewing the PMA supplement submitted in June 2025, a key binary catalyst for launch timing.
